LCM
TRML

Laurion Capital Management’s Tourmaline Bio TRML Stock Holding History

Laurion Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,792
Closed -$820K – 757
2024
Q1 		$820K Hold
35,792
– – 0.01% 393
2023
Q4 		$937K Buy
+35,792
New +$716K 0.01% 348
2023
Q2 		– Sell
-29,842
Closed -$561K – 696
2023
Q1 		$561K Hold
29,842
– – ﹤0.01% 331
2022
Q4 		$304K Hold
29,842
– – ﹤0.01% 371
2022
Q3 		$785K Hold
29,842
– – ﹤0.01% 380
2022
Q2 		$1.35M Hold
29,842
– – 0.02% 260
2022
Q1 		$2.94M Hold
29,842
– – 0.04% 189
2021
Q4 		$4.56M Hold
29,842
– – 0.05% 203
2021
Q3 		$4.05M Hold
29,842
– – 0.02% 370
2021
Q2 		$4.38M Buy
+29,842
New +$4.57M 0.02% 292

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Laurion Capital Management's TRML Position: Q2 2024 in Review

Laurion Capital Management sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 35,792 shares — an estimated $820K sold.

Laurion Capital Management first reported a position in TRML in Q2 2021 and held it in 10 quarters. The position peaked at $4.56M in Q4 2021. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

  • Laurion Capital Management reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 35,792 Tourmaline Bio shares in Q2 2024, an estimated $820K.
  • Laurion Capital Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 10 quarters.
  • Laurion Capital Management's Tourmaline Bio position peaked at $4.56M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.